Tokyo, Sept 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. and Santen Pharmaceutical Co., Ltd. announced today that they have entered into an option agreement which grants Santen rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology.
